Quantum-Si (NASDAQ:QSI) Posts Earnings Results, Beats Expectations By $0.02 EPS

Quantum-Si (NASDAQ:QSI) posted its quarterly earnings data on Thursday. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02, FiscalAI reports. Quantum-Si had a negative net margin of 5,605.88% and a negative return on equity of 46.05%. The company had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.30 million.

Here are the key takeaways from Quantum-Si’s conference call:

• Proteus reached a major technical milestone — Quantum-Si completed sequencing on fully integrated Proteus instruments detecting 17 amino acids and expects 18 by end-2026 with detection of all 20 during 2026 and a full sequencing kit in 2027, which management frames as a significant de?risking versus Platinum.
• Early customer evaluations and commercial preparation look constructive — a prototype customer reported ~2x average read length and more amino acids detected versus Platinum, the company is running Proteus Roadshows and plans broader sample evaluations to build a buyer funnel, and has positioned Proteus at $425,000 versus >$1M for comparable high-end mass spec alternatives.
• Financial position supports the plan — Quantum?Si had $190.4M in cash and investments at 3/31/26 and guides 2026 adjusted OpEx ? $98M and cash use ? $93M, projecting runway into Q2 2028 to fund Proteus completion and launch readiness.
• Near?term revenue will remain limited — Q1 revenue was only $258k and the company reiterates 2026 revenue around ? $1M, describing 2026 as a transition year with modest capital sales as customers delay purchases pending Proteus availability.

Quantum-Si Trading Down 7.5%

Shares of QSI traded down $0.07 during mid-day trading on Friday, reaching $0.91. The company’s stock had a trading volume of 13,112,028 shares, compared to its average volume of 6,228,345. The stock has a market cap of $196.16 million, a PE ratio of -1.78 and a beta of 3.15. Quantum-Si has a 52 week low of $0.69 and a 52 week high of $3.10. The company’s fifty day moving average price is $0.90 and its two-hundred day moving average price is $1.20.

Insider Buying and Selling at Quantum-Si

In other news, CEO Jeffrey Alan Hawkins sold 83,712 shares of the business’s stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $1.01, for a total value of $84,549.12. Following the completion of the sale, the chief executive officer directly owned 3,776,135 shares in the company, valued at approximately $3,813,896.35. The trade was a 2.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Paula Dowdy acquired 109,890 shares of the stock in a transaction dated Thursday, March 5th. The stock was acquired at an average price of $0.95 per share, with a total value of $104,395.50. Following the completion of the acquisition, the director owned 269,107 shares in the company, valued at approximately $255,651.65. The trade was a 69.02% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders have sold 212,904 shares of company stock valued at $205,021. Insiders own 22.04% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in QSI. Invesco Ltd. increased its stake in shares of Quantum-Si by 177.7% in the first quarter. Invesco Ltd. now owns 103,657 shares of the company’s stock worth $124,000 after buying an additional 66,336 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Quantum-Si by 23.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,552 shares of the company’s stock worth $85,000 after buying an additional 13,546 shares during the period. Millennium Management LLC purchased a new position in shares of Quantum-Si in the first quarter worth $4,721,000. JPMorgan Chase & Co. increased its stake in shares of Quantum-Si by 15.6% in the second quarter. JPMorgan Chase & Co. now owns 66,656 shares of the company’s stock worth $131,000 after buying an additional 9,005 shares during the period. Finally, Rhumbline Advisers increased its stake in shares of Quantum-Si by 36.0% in the second quarter. Rhumbline Advisers now owns 203,967 shares of the company’s stock worth $400,000 after buying an additional 53,994 shares during the period. 39.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on QSI. Canaccord Genuity Group dropped their price objective on shares of Quantum-Si from $1.50 to $1.00 and set a “hold” rating for the company in a report on Wednesday, March 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Quantum-Si in a report on Friday, March 27th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $3.25.

Quantum-Si Company Profile

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.